HUT74458A - Desogestrel-containing transdermal application agent - Google Patents

Desogestrel-containing transdermal application agent Download PDF

Info

Publication number: HUT74458A
Authority: HU; Hungary
Prior art keywords: transdermal; adhesive; desogestrel; estrogen; optionally
Prior art date: 1994-02-18

Application number

HU9602286A

Other languages

English (en)

Hungarian (hu)

Other versions

HU9602286D0 (en

Inventor

Clemens Guenther

Ralph Lipp

Jutta Riedl

Ulrich Taeuber

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-18

Filing date

1995-02-09

Publication date

1996-12-30

1995-02-09 Application filed by Schering Ag filed Critical Schering Ag

1996-10-28 Publication of HU9602286D0 publication Critical patent/HU9602286D0/hu

1996-12-30 Publication of HUT74458A publication Critical patent/HUT74458A/hu

Links

RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 title claims description 29
229960004976 desogestrel Drugs 0.000 title claims description 29
239000000203 mixture Substances 0.000 claims description 41
239000011159 matrix material Substances 0.000 claims description 30
229940011871 estrogen Drugs 0.000 claims description 21
239000000262 estrogen Substances 0.000 claims description 21
239000004480 active ingredient Substances 0.000 claims description 20
239000000853 adhesive Substances 0.000 claims description 18
230000001070 adhesive effect Effects 0.000 claims description 16
239000003961 penetration enhancing agent Substances 0.000 claims description 15
239000003623 enhancer Substances 0.000 claims description 8
150000002148 esters Chemical class 0.000 claims description 8
230000035515 penetration Effects 0.000 claims description 8
239000000583 progesterone congener Substances 0.000 claims description 6
229960005309 estradiol Drugs 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 4
229930182833 estradiol Natural products 0.000 claims description 4
201000009273 Endometriosis Diseases 0.000 claims description 3
208000001132 Osteoporosis Diseases 0.000 claims description 3
206010036618 Premenstrual syndrome Diseases 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
238000002425 crystallisation Methods 0.000 claims description 3
230000008025 crystallization Effects 0.000 claims description 3
230000001419 dependent effect Effects 0.000 claims description 3
239000003112 inhibitor Substances 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
230000006641 stabilisation Effects 0.000 claims description 3
238000011105 stabilization Methods 0.000 claims description 3
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims description 2
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 2
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 2
229960001348 estriol Drugs 0.000 claims description 2
IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 claims description 2
229960001390 mestranol Drugs 0.000 claims description 2
208000029522 neoplastic syndrome Diseases 0.000 claims description 2
229920000058 polyacrylate Polymers 0.000 claims description 2
239000010410 layer Substances 0.000 description 22
238000009472 formulation Methods 0.000 description 12
239000012790 adhesive layer Substances 0.000 description 8
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
239000002904 solvent Substances 0.000 description 7
-1 tetrahydrofuran Chemical class 0.000 description 7
GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 6
229920006267 polyester film Polymers 0.000 description 6
229940100640 transdermal system Drugs 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
239000007788 liquid Substances 0.000 description 5
150000001875 compounds Chemical class 0.000 description 4
239000011888 foil Substances 0.000 description 4
229920000728 polyester Polymers 0.000 description 4
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
235000013772 propylene glycol Nutrition 0.000 description 3
239000011241 protective layer Substances 0.000 description 3
239000003270 steroid hormone Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229920002367 Polyisobutene Polymers 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
238000001035 drying Methods 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
239000000463 material Substances 0.000 description 2
150000004702 methyl esters Chemical class 0.000 description 2
235000021313 oleic acid Nutrition 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000013464 silicone adhesive Substances 0.000 description 2
230000007704 transition Effects 0.000 description 2
MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
BOSAWIQFTJIYIS-UHFFFAOYSA-N 1,1,1-trichloro-2,2,2-trifluoroethane Chemical compound FC(F)(F)C(Cl)(Cl)Cl BOSAWIQFTJIYIS-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
229920013683 Celanese Polymers 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
RDOFJDLLWVCMRU-UHFFFAOYSA-N Diisobutyl adipate Chemical compound CC(C)COC(=O)CCCCC(=O)OCC(C)C RDOFJDLLWVCMRU-UHFFFAOYSA-N 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
JQIYNMYZKRGDFK-RUFWAXPRSA-N Estradiol dipropionate Chemical compound C1CC2=CC(OC(=O)CC)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 JQIYNMYZKRGDFK-RUFWAXPRSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
235000021360 Myristic acid Nutrition 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229920005987 OPPANOL® Polymers 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
UETILLFPBWWSTP-BAQMTIIXSA-N [(8R,9S,13S,14S)-3-decanoyloxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] decanoate Chemical compound C1CC2=CC(OC(=O)CCCCCCCCC)=CC=C2[C@@H]2[C@@H]1[C@@H]1CCC(OC(=O)CCCCCCCCC)[C@@]1(C)CC2 UETILLFPBWWSTP-BAQMTIIXSA-N 0.000 description 1
CDYDMZIFERBGHJ-GGFYAANGSA-N [(8R,9S,13S,14S)-3-hexanoyloxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] hexanoate Chemical compound C1CC2=CC(OC(=O)CCCCC)=CC=C2[C@@H]2[C@@H]1[C@@H]1CCC(OC(=O)CCCCC)[C@@]1(C)CC2 CDYDMZIFERBGHJ-GGFYAANGSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000003522 acrylic cement Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
239000002519 antifouling agent Substances 0.000 description 1
208000011803 breast fibrocystic disease Diseases 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000011340 continuous therapy Methods 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
238000007872 degassing Methods 0.000 description 1
229940077569 desogestrel and estrogen Drugs 0.000 description 1
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
229940031769 diisobutyl adipate Drugs 0.000 description 1
229940031578 diisopropyl adipate Drugs 0.000 description 1
229940031569 diisopropyl sebacate Drugs 0.000 description 1
XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229950010215 estradiol dipropionate Drugs 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
239000004744 fabric Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
229920002313 fluoropolymer Polymers 0.000 description 1
239000004811 fluoropolymer Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000003152 gestagenic effect Effects 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
229940044513 implanon Drugs 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
229920003052 natural elastomer Polymers 0.000 description 1
229920001194 natural rubber Polymers 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
150000002889 oleic acids Chemical class 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000013047 polymeric layer Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000000926 separation method Methods 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229920003048 styrene butadiene rubber Polymers 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229920003051 synthetic elastomer Polymers 0.000 description 1
239000005061 synthetic rubber Substances 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

HU9602286A 1994-02-18 1995-02-09 Desogestrel-containing transdermal application agent HUT74458A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4405899A DE4405899A1 (de)	1994-02-18	1994-02-18	Mittel zur transdermalen Applikation enthaltend Desogestrel

Publications (2)

Publication Number	Publication Date
HU9602286D0 HU9602286D0 (en)	1996-10-28
HUT74458A true HUT74458A (en)	1996-12-30

Family

ID=6511045

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU9602286A HUT74458A (en)	1994-02-18	1995-02-09	Desogestrel-containing transdermal application agent

Country Status (10)

Country	Link
EP (1)	EP0744943A1 (fr)
JP (1)	JPH09508911A (fr)
KR (1)	KR970701538A (fr)
AU (1)	AU1578695A (fr)
CA (1)	CA2183544A1 (fr)
DE (1)	DE4405899A1 (fr)
HU (1)	HUT74458A (fr)
NO (1)	NO963433L (fr)
NZ (1)	NZ279226A (fr)
WO (1)	WO1995022321A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19600347A1 (de) *	1996-01-08	1997-07-10	Lohmann Therapie Syst Lts	Hauthaftende pharmazeutische Zubereitung, insbesondere TTS zur Abgabe von 17-beta-Estradiol an den menschlichen Organismus
FR2749586B1 (fr) *	1996-06-11	1998-08-07	Hoechst Marion Roussel Inc	Nouveaux dispositifs destines a l'administration transdermique de la trimegestone, leur procede de preparation et leur application a titre de medicaments
DE19629468A1 (de) *	1996-07-11	1998-01-15	Schering Ag	Transdermale therapeutische Systeme
DE19701949A1 (de) *	1997-01-13	1998-07-16	Jenapharm Gmbh	Transdermales therapeutisches System
AU2223600A (en) *	1999-01-06	2000-07-24	Cedars-Sinai Medical Center	Hormone replacement for breast cancer patients
DE10019171A1 (de) *	2000-04-07	2001-10-18	Schering Ag	Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
DE102010040299A1 (de) *	2010-09-06	2012-03-08	Bayer Schering Pharma Aktiengesellschaft	Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
BRPI1003661A2 (pt) *	2010-09-15	2013-01-08	Libbs Farmacêutica Ltda	associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose
EP2806862A2 (fr) *	2012-01-27	2014-12-03	Agile Therapeutics, Inc.	Administration d'hormones par voie transdermique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4210165A1 (de) *	1991-07-30	1993-02-04	Schering Ag	Transdermale therapeutische systeme
DE4210711A1 (de) *	1991-10-31	1993-05-06	Schering Ag Berlin Und Bergkamen, 1000 Berlin, De	Transdermale therapeutische systeme mit kristallisationsinhibitoren
DE4227989A1 (de) *	1992-08-21	1994-06-09	Schering Ag	Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4229820C2 (de) *	1992-09-07	1998-12-03	Jenapharm Gmbh	Pharmazeutische Zubereitung auf Gestagen-Basis

1994
- 1994-02-18 DE DE4405899A patent/DE4405899A1/de not_active Withdrawn
1995
- 1995-02-09 EP EP95907661A patent/EP0744943A1/fr not_active Withdrawn
- 1995-02-09 KR KR1019960704500A patent/KR970701538A/ko not_active Withdrawn
- 1995-02-09 JP JP7521560A patent/JPH09508911A/ja active Pending
- 1995-02-09 NZ NZ279226A patent/NZ279226A/en unknown
- 1995-02-09 CA CA002183544A patent/CA2183544A1/fr not_active Abandoned
- 1995-02-09 WO PCT/EP1995/000481 patent/WO1995022321A1/fr not_active Ceased
- 1995-02-09 HU HU9602286A patent/HUT74458A/hu unknown
- 1995-02-09 AU AU15786/95A patent/AU1578695A/en not_active Abandoned
1996
- 1996-08-16 NO NO963433A patent/NO963433L/no unknown

Also Published As

Publication number	Publication date
KR970701538A (ko)	1997-04-12
HU9602286D0 (en)	1996-10-28
EP0744943A1 (fr)	1996-12-04
CA2183544A1 (fr)	1995-08-24
DE4405899A1 (de)	1995-08-24
NO963433L (no)	1996-08-16
WO1995022321A1 (fr)	1995-08-24
JPH09508911A (ja)	1997-09-09
AU1578695A (en)	1995-09-04
NZ279226A (en)	1998-05-27

Legal Events

Date	Code	Title	Description
1999-11-29	DFD9	Temporary prot. cancelled due to non-payment of fee

Publication	Publication Date	Title
RU2154455C2 (ru)	2000-08-20	Чрескожные терапевтические системы, содержащие половые стероиды
US5788984A (en)	1998-08-04	Gestodene-containing agent for transdermal administration
DK171138B1 (da)	1996-07-01	Transdermal absorptionsdosisenhed til behandling af postmenopausesyndrom
AU687013B2 (en)	1998-02-19	Transdermal application agent containing 3-keto-desogestrel
US5858394A (en)	1999-01-12	Agent for transdermal administration that contains gestodene esters
HU228434B1 (en)	2013-03-28	Transdermal medicament for administering 17-deacetyl norgestimate alone or in combination with an estrogen
JP2014051507A (ja)	2014-03-20	避妊及びホルモン補充のためのノルエルゲストロミンを含む経皮治療システム
JP2001508070A (ja)	2001-06-19	ホルモン剤供給のための経皮吸収治療システム
HUT74458A (en)	1996-12-30	Desogestrel-containing transdermal application agent
RU2044541C1 (ru)	1995-09-27	Способ получения лечебного средства для трансдермального применения
JPH11509222A (ja)	1999-08-17	１３−エチル−１７β−ヒドロキシ−１１−メチレン−１８，１９−ジノル−１７α−プレグン−４−エン−２０−イン−３−オンのエステルを含む経皮投与のための剤
JPH07101864A (ja)	1995-04-18	経皮吸収貼付剤
AU724308B2 (en)	2000-09-14	Transdermal therapeutic systems that contain sex steroids
JPH09510697A (ja)	1997-10-28	１４α，１７α−エタノエストラ−１，３，５（１０）−トリエン−３，１７β−ジオールを含有する経皮投与のための薬剤
KR20010029770A (ko)	2001-04-16	에스트로겐 작용물질-길항물질을 포함하는 경피 투여용조성물
HUT74616A (en)	1997-01-28	Agent, intended for transdermal administration, containing 14alfa, 17alfa-ethanoestra-1,3,5(10)-triene-3,17beta-diol
CA2182188A1 (fr)	1995-08-03	Substance pour application transdermique contenant du 14.alpha.,17.alpha.-ethanoestra-1,3,5(10)-triene-3,17.beta.-diol